atlasAdd
2026-04-03 · earnings-review · Arcutis delivered a strong Q4 FY25 that exceeded my expectations on revenue, margins, and cash flow · Conviction 3/5
Open analysis → · PDF unavailable
Preview
# ARQT — Q4 FY25 Earnings Review (Atlas)
> Date: 2026-04-03
> Quarter: Q4 FY25 (Dec-2025)
> Market cap: ~$3.0B | EV/TTM Rev: 7.7x | Revenue growth: 81.4% YoY
## Verdict
Arcutis delivered a strong Q4 FY25 that exceeded my expectations on revenue, margins, and cash flow. Net product revenue of $127.5M (+84% YoY, +31% QoQ) re-accelerated sequentially after a moderate Q2-Q3 growth deceleration, and the company achieved its first meaningfully positive OCF quarter ($26.2M) ahead of schedule. The profitability inflection is now structurally confirmed: two consecutive GAAP profitable quarters, operating margin expanding from -10.6% to +14.2% YoY. FY2026 guidance was raised to $480-495M (+30% YoY at midpoint), conservative given the Q4 annualized run-rate of ~$510M. The thesis is intact and marginally strengthening. The single-molecule risk and ~2030 patent cliff remain the binding constraints on conviction.
**Conviction: 3/5** (Hold / Watchlist — thesis intact, execution excellent, but single-product pharma risk and growth deceleration to ~30% cap conviction at current valuation)
## Qualification Gate
| Criterion | Threshold | Actual | Pass/Fail |
|-----------|-----------|--------|-----------|
| Revenue YoY growth | >30% | 81.4% (Q4 FY25) | PASS |
| Gross margin | >60% (>70% pref) | 91.0% | PASS |
| Revenue per quarter | >$50M | $129.5M | PASS |
| Data availability | 4+ quarters | 16 quarters | PASS |
| Share dilution | <10% annual | 2.6% (125.0M to 128.3M basic) | PASS |
| GAAP profitability trajectory | Improving/positive | Positive Q3-Q4 FY25, expanding | PASS |
All gates passed.
## Six-Factor Score
| Factor | Rating | Detail |
|--------|--------|--------|
| Growth | Strong | 81.4% YoY Q4; FY25 full year +91%. Net product revenue +84% YoY, +31% QoQ. Sequential growth re-accelerated from +22.3% to +31.2% on net product revenue. |
| Trajectory | Decelerating (hyper to strong) | YoY growth normalizing from 91% (FY25) to ~30% (FY26 guide). QoQ sequential trend is re
*…truncated*
Preview
# ARQT — Q4 FY25 Earnings Review (WSM)
> Date: 2026-04-06
> Quarter: Q4 FY25 (Dec-2025) | Reported: 2026-02-25
> Price: ~$22.54 | Market cap: ~$3.06B | EV: ~$2.94B
---
## Verdict
**This is a beat-and-raise from a company achieving profitability inflection ahead of schedule.** Net product revenue of $127.5M (+84% YoY, +31% QoQ) re-accelerated sequentially after two quarters of moderating QoQ growth, operating margin swung from -10.6% to +14.2% YoY, and OCF hit $26.2M — the first meaningfully positive quarter, well ahead of management's own timeline. FY2026 guidance raised $25M to $480-495M, conservative against a Q4 annualized run-rate of $510M. Incremental operating margin of 44.8% confirms the business model scales beautifully.
I haven't written about ARQT before, but applying my framework: this hits multiple green flags simultaneously — FCF inflection, operating leverage kicking in, sequential re-acceleration at scale, and management underpromise/overdeliver on guidance. The binding constraints remain single-molecule concentration and the ~2030 patent cliff.
**Thesis: Intact / Strengthening** | **Conviction: 3/5** | **Action: Watchlist — would add on pullback to ~5x run-rate revenue (~$19)**
---
## The Numbers
### 12-Quarter Revenue Grid
| | Q1 FY23 | Q2 FY23 | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | **Q4 FY25** |
| | Mar-23 | Jun-23 | Sep-23 | Dec-23 | Mar-24 | Jun-24 | Sep-24 | Dec-24 | Mar-25 | Jun-25 | Sep-25 | **Dec-25** |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue ($m) | 2.8 | 5.2 | 38.1 | 13.5 | 49.6 | 30.9 | 44.8 | 71.4 | 65.8 | 81.5 | 99.2 | **129.5** |
| QoQ % | -6.7% | +85.7% | +633% | -64.6% | +267% | -37.7% | +45.0% | +59.4% | -7.8% | +23.9% | +21.7% | **+30.5%** |
| YoY % | -- | -- | -- | -- | +1671% | +494% | +17.6% | +429% | +32.7% | +164% | +121% | **+81.4%** |
| Net Prod Rev ($m) | -- | -- | -- | -- | -- | -- | -- | 69.4 | 63.8 | 79.5 | 97.2 | **127.5** |
| NP Rev Qo
*…truncated*
Rolling earnings (raw)
# ARQT — Earnings Rolling Summary
> Last updated: 2026-04-03
> Covers: Q1 FY25 -> Q4 FY25 (4 quarters)
> Latest ER file: earnings/ARQT/Q4_FY25.md
## Trajectory
Arcutis executed a textbook commercial ramp in FY2025: net product revenue grew from $63.8M (Q1) to $127.5M (Q4), a doubling within the year. The company crossed the GAAP profitability inflection in Q3 FY25 and expanded margins in Q4. Sequential revenue growth re-accelerated in Q4 (+31.2% QoQ on net product revenue), reversing a gradual deceleration trend in Q2-Q3. FY2026 guidance of $480-495M implies ~30% growth as the base normalizes.
## Promise Tracker
| Quarter | Promise | Delivered? | Notes |
|---------|---------|-----------|-------|
| Q3 FY25 | FY2026 guidance $455-470M | Beat — raised | Raised to $480-495M at Q4 FY25 earnings |
| Q4 FY25 | FY2026 revenue $480-495M | Pending | |
| Q4 FY25 | Positive OCF every quarter FY2026 | Pending | Q4 FY25 OCF was +$26.2M |
| Q4 FY25 | GTN stable in "50s" FY2026 | Pending | |
| Q4 FY25 | Infant AD sNDA Q2 2026 | Pending | INTEGUMENT-Infant: 58% EASI-75 wk4 |
| Q4 FY25 | Peds psoriasis PDUFA June 29, 2026 | Pending | Regulatory timeline |
| Q4 FY25 | Vitiligo Phase II decision Q4 2026 | Pending | |
| Q4 FY25 | HS Phase II decision 2027 | Pending | |
## Language Shift Monitor
| Topic | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|-------|---------|---------|---------|---------|
| Demand | *No transcript* | *No transcript* | *Guidance only: $455-470M* | "Robust" / "steady" / "strong" — bullish. 45% share cited unprompted. |
| Competition | *Unknown* | *Unknown* | *Unknown* | Not directly addressed. Market framing positions TCS displacement as large, low-risk opportunity. |
| Margins/Efficiency | *Cash burn: OCF -$30.4M* | *Op loss narrowing: -$14.6M* | *First profitable Q: +$8.5M op income* | Emphatic: "ahead of schedule" on cash flow. All-4-quarters-2026 positive OCF commitment. |
| Product/Innovation | *Revenue ramp* | *Revenue ramp* | *Initial 2026 guidance* | Three-pillar framework (Grow/Expand/Build). Pipeline emphasis: infant AD, peds psoriasis, vitiligo, HS, ARQ-234. |
## Analyst Concern Tracker
| Concern | First Raised | Status | Resolution |
|---------|-------------|--------|------------|
| Single-product revenue concentration | Pre-FY25 | Active | ARQ-234 Phase I initiated but years from revenue. No near-term diversification. |
| Growth deceleration | Q4 FY25 | Monitoring | FY2026 ~30% growth guided. Expected math; QoQ still re-accelerating. |
| Kowa termination / PC channel risk | Jan 2026 | Active | Internal 30-rep pilot replacing Kowa. Execution unproven. |
| Trade receivables elevated | Q4 FY25 | Monitoring | $146.2M (1.13x quarterly revenue). First observation — need Q1 FY26 to compare. |
| Valuation after 100% rally | Feb 2026 | Monitoring | ~7.7x TTM, ~5.9x forward at ~$3.0B mkt cap. SA analysts split bull/hold. |
## Quarter-by-Quarter Verdict
| | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---------|---------|---------|---------|
| Revenue ($m) | 65.8 | 81.5 | 99.2 | 129.5 |
| YoY % | 32.7% | 163.8% | 121.4% | 81.4% |
| Net Prod Rev ($m) | 63.8 | 79.5 | 97.2 | 127.5 |
| QoQ % (NP Rev) | -8.1% | +24.6% | +22.3% | +31.2% |
| Op Income ($m) | -24.5 | -14.6 | +8.5 | +18.4 |
| Key Signal | Ramp continues | Loss narrowing | Profitability inflection | Accelerating QoQ + profitable |
| Concern | Q1 seasonal dip | Growth sustainability | Can margins hold? | Receivables elevated; Kowa exit |
## Recent Conferences
| Date | Event | Key Incremental Info |
|------|-------|---------------------|
| Jan 2026 | JP Morgan Healthcare | 2026 strategic priorities announced; Kowa termination disclosed |
| Mar 2026 | Needham Healthcare | "Strategic Growth in Dermatology" presentation |
| Mar 2026 | AAD Annual Meeting | Late-breaking infant AD data presented (INTEGUMENT-Infant Phase 2) |
| Apr 2026 | Needham Virtual Healthcare Conference | Fireside chat Apr 14 — strategic growth in dermatology |
## Source Log
| Date | Persona | What was changed |
|------|---------|-----------------|
| 2026-04-01 | atlas | Initial creation from stock analysis. Populated all sections from Q4 FY25 data + scout brief. No prior rolling file existed. |
| 2026-04-02 | atlas | Stock analysis refresh. Updated valuation with live market cap $2.97B. Added Needham conference (Apr 14) to recent conferences. No financial data changes (same Q4 FY25 quarter). All promise tracker statuses unchanged. |
| 2026-04-03 | atlas | Earnings review (Q4 FY25). Created Q4_FY25.md quarter file. Linked ER file in header. Updated valuation concern with current multiples (7.7x TTM, 5.9x fwd). No promise tracker changes — all still pending. |
| 2026-04-06 | wsm | Earnings review (Q4 FY25). First WSM analysis of ARQT. No financial data changes — same Q4 FY25 quarter as atlas. Added incremental operating margin analysis (44.8%), valuation at ~$22.54 (P/S 5.9x run-rate), and WSM-specific divergence from Atlas on pharma growth dynamics. All promise tracker statuses unchanged (all pending). |